NCT00003513View on ClinicalTrials.gov

Antineoplaston Therapy in Treating Patients With Metastatic, Recurrent, or Refractory Neuroblastoma

PHASE2TerminatedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

December 16, 1996

Primary Completion Date

March 29, 1999

Study Completion Date

March 29, 1999

Conditions
Neuroblastoma
Interventions
DRUG

Antineoplaston therapy (Atengenal + Astugenal)

"Patients With Metastatic, Recurrent, or Refractory Neuroblastoma will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."

Trial Locations (1)

77055-6330

Burzynski Clinic, Houston

Sponsors
All Listed Sponsors
lead

Burzynski Research Institute

OTHER